Roundview Capital’s CASI Pharmaceuticals CASI Stock Holding History

Roundview Capital’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,811	Closed	-$31K	–	281
2022 Q1	$31K	Sell	3,811 -8,434	-69%	-$66.2K	﹤0.01%	291
2021 Q4	$98K	Hold	12,245	–	–	0.01%	296
2021 Q3	$146K	Hold	12,245	–	–	0.02%	285
2021 Q2	$190K	Sell	12,245 -2,123	-15%	-$35.7K	0.02%	274
2021 Q1	$345K	Buy	+14,368	New	+$403K	0.04%	237

Other funds holding CASI

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return

WSC

Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Roundview Capital's CASI Position: Q2 2022 in Review

Roundview Capital sold out of CASI Pharmaceuticals (CASI) in Q2 2022, closing a stake of 3,811 shares — an estimated $31K sold.

Roundview Capital first reported a position in CASI in Q1 2021 and held it in 5 quarters. The position peaked at $345K in Q1 2021. 24 funds tracked by Wall St. Rank hold CASI as of Q2 2022.

Roundview Capital reported no remaining CASI Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Roundview Capital sold 3,811 CASI Pharmaceuticals shares in Q2 2022, an estimated $31K.
Roundview Capital first reported a position in CASI Pharmaceuticals in Q1 2021 and held it in 5 quarters.
Roundview Capital's CASI Pharmaceuticals position peaked at $345K in Q1 2021.
24 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2022.

Based on Roundview Capital's 13F filing for Q2 2022, filed 11 Aug 2022.